OTC Markets OTCPK - Delayed Quote USD

Xvivo Perfusion AB (publ) (XVIPF)

Compare
47.00 0.00 (0.00%)
At close: October 9 at 4:00 PM EDT
Loading Chart for XVIPF
DELL
  • Previous Close 49.00
  • Open 49.00
  • Bid 46.36 x 40000
  • Ask 48.13 x 40000
  • Day's Range 48.94 - 49.00
  • 52 Week Range 19.90 - 52.38
  • Volume 200
  • Avg. Volume 95
  • Market Cap (intraday) 1.551B
  • Beta (5Y Monthly) 2.10
  • PE Ratio (TTM) 123.68
  • EPS (TTM) 0.38
  • Earnings Date Oct 24, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden, the United States, the Netherlands, Italy, North and South America, Europe, the Middle East, Africa, the Asia Pacific, and Oceania. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. The company was incorporated in 1998 and is headquartered in M?lndal, Sweden.

www.xvivogroup.com

152

Full Time Employees

December 31

Fiscal Year Ends

Recent News: XVIPF

View More

Performance Overview: XVIPF

Trailing total returns as of 10/10/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

XVIPF
106.14%
OMX Stockholm 30 Index
7.33%

1-Year Return

XVIPF
86.51%
OMX Stockholm 30 Index
20.66%

3-Year Return

XVIPF
10.20%
OMX Stockholm 30 Index
14.90%

5-Year Return

XVIPF
174.85%
OMX Stockholm 30 Index
58.88%

Compare To: XVIPF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: XVIPF

View More

Valuation Measures

Annual
As of 10/9/2024
  • Market Cap

    1.55B

  • Enterprise Value

    1.51B

  • Trailing P/E

    123.24

  • Forward P/E

    90.09

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    21.44

  • Price/Book (mrq)

    7.57

  • Enterprise Value/Revenue

    22.30

  • Enterprise Value/EBITDA

    117.03

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    17.28%

  • Return on Assets (ttm)

    1.32%

  • Return on Equity (ttm)

    6.84%

  • Revenue (ttm)

    698.72M

  • Net Income Avi to Common (ttm)

    120.74M

  • Diluted EPS (ttm)

    0.38

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    480.77M

  • Total Debt/Equity (mrq)

    1.34%

  • Levered Free Cash Flow (ttm)

    -77.76M

Company Insights: XVIPF

People Also Watch